What do the next 100 years hold for pneumococcal vaccination?

Expert Review of Vaccines

Volumn 9, Issue 11, 2010, Pages 1241-1244

  Rijkers, Ger T ^a,b,c   Van Mens, Suzan P ^a   Van Velzen Blad, Heleen ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

conjugate vaccine; meningitis; personalized vaccination; pneumococcus; pneumonia; polysaccharide; risk groups; serotype replacement

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; SMALLPOX VACCINE;

BACTERIAL COLONIZATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; IMMUNITY; INFECTION RISK; INFECTION SENSITIVITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SMALLPOX; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 78649374597     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.127     Document Type: Editorial

References (46)

1. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine 16, 1396-1400 (1998).
2. Wright AE, Parry Morgan W, Colebrook L, Dodgson RW Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved with it. Lancet 1, 1-10 (1914).
3. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 10, 2759-2762 (1995).
4. Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identifcation of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology 156, 555-560 (2010).
5. Briles DE, Hollingshead SK, Paton JC et al Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188, 339-348 (2003).
6. Briles DE, Hollingshead SK, King J et al Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182, 1694-1701 (2000).
7. Ogunniyi AD, LeMessurier KS, Graham RM et al. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect. Immun. 75, 1843-1851 (2007).
8. Robbins JB, Schneerson R. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides. Bull. Eur. Physiopathol. Respir. 19, 215-226 (1983).
9. Dixon JM, Lipinski AE. Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine. Can. Med. Assoc. J. 25, 263-267 (1981).
10. Cornu C, Yzèbe D, Léophonte P et al. Effcacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19, 4780-4790 (2001).
11. Robbins FC, Robbins JB. Current status and prospects for some improved and new bacterial vaccines. Ann. Rev. Public Health 7, 105-125 (1986).
12. Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA et al. EPIVAC Study Group. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect. Dis. 10, 73 (2010).
13. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin. Infect. Dis. 26, 1117-1123 (1998).
14. Griffoen AW, Franklin SW, Zegers BJ, Rijkers GT. Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin. Immunol Immunopathol. 69, 1-8 (1993).
15. Griffoen AW, Rijkers GT, Janssens-Korpela P, Zegers BJ. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect. Immun. 59, 1839-1845 (1991).
16. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176, 154-170 (2000).
17. Avery OT, Goebel WF. Chemoimmunological studies on conjugated carbohydrate-proteins: V. The immunological specifcity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54, 437-447 (1931).
18. Morris SK, Moss WJ, Halsey N. Haemophilus infuenzae type b conjugate vaccine use and effectiveness. Lancet Infect. Dis. 8, 435-443 (2008).
19. Ojo LR, O'Loughlin RE, Cohen AL et al Global use of Haemophilus infuenzae type b conjugate vaccine. Vaccine 8(7), 435-443 (2010).
20. Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101, 604-611 (1998).
21. Black S, Shinefeld H, Fireman B et al. Effcacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187-195 (2000).
22. Whitney CG, Farley MM, Hadler J et al. Active bacterial core surveillance of the emerging infections program network. decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003).
23. Fenner F, Henderson DA, Arita L, Jezek Z, Ladnyi ID. Smallpox and its Eradication. WHO, Geneva, Switzerland (1988).
24. Beall B, McEllistrem MC, Gertz RE Jr et al.; Active Bacterial Core Surveillance Team. Pre-and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J. Clin. Microbiol. 44, 999-1017 (2006).
25. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297, 1784-1792 (2007).
26. Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med. 360, 244-256 (2009).
27. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev. Vaccines 9, 229-236 (2010).
28. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28, 4249-4259 (2010).
29. Hausdorff W P, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27, 7257-7269 (2009).
30. van Effelterre T, Moore MR, Fierens F et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 28, 3650-3560 (2010).
31. Antao VC, Hausdorff WP. Global epidemiology of pneumococcal disease-new prospects for vaccine control. Adv. Exp. Med. Biol. 634, 19-29 (2009).
32. De Wals P, Black S, Borrow R, Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus infuenzae diseases: a new simulation model. Clin. Ther. 31, 2152-2169 (2009).
33. Meerveld-Eggink A, de Weerdt O, Rijkers GT, van Velzen-Blad H, Biesma DH. Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in The Netherlands. Vaccine 26, 6975-6979 (2008).
34. Leemans R, Harms G, Rijkers GT, Timens W. Spleen autotransplantation provides restoration of functional splenic lymphoid compartments and improves the humoral immune response to pneumococcal polysaccharide vaccine. Clin. Exp. Immunol. 117, 596-604 (1999).
35. Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and infuenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect. Dis. 10, 219 (2010).
36. Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and Haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 19, 1671-1677 (2001).
37. Segal BH, Freifeld AG, Baden LR et al. Prevention and treatment of cancer-related infections. J. Natl Comp. Cancer Netw. 6, 122-174 (2008).
38. van der Velden AM, Claessen AM, van Velzen-Blad H et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine 25, 8512-8517 (2007).
39. Rijkers GT, Sanders LA, Zegers BJ. Anti-capsular polysaccharide antibody defciency states. Immunodefciency 5, 1-21 (1993).
40. Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine effcacy among older adults. Neth. J. Med. 66, 378-383 (2008).
41. Sanders LA, Feldman RG, Voorhorst-Ogink MM et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun. 63, 73-81 (1995).
42. Wiertsema SP, Baynam G, Khoo SK et al. Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response. Vaccine 25, 306-313 (2007).
43. Wiertsema SP, Veenhoven RH, Walraven V et al. Pneumococcal vaccine effcacy for mucosal pneumococcal infections depends on Fcy receptor IIa polymorphism. Vaccine 24, 792-797 (2006).
44. Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging feld of vaccinomics. Expert Opin. Biol. Ther. 8, 1659-1667 (2008).
45. Reif DM, Motsinger-Reif AA, McKinney BA, Rock MT, Crowe JE Jr, Moore JH. Integrated analysis of genetic and proteomic data identifes biomarkers associated with adverse events following smallpox vaccination. Genes Immun. 10, 112-119 (2009).
46. Brooks WA. A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. Vaccine 27, 619-623 (2009).